minoxidil has been researched along with Cardiomyopathy, Hypertrophic in 2 studies
Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.
Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Minoxidil was used to treat 112 patients with severe and refractory hypertension during a period of 8 years." | 3.66 | Unusual cases of resistance to minoxidil therapy. ( Wells, JO, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wells, JO | 1 |
| Fatkin, D | 1 |
| McConnell, BK | 1 |
| Mudd, JO | 1 |
| Semsarian, C | 1 |
| Moskowitz, IG | 1 |
| Schoen, FJ | 1 |
| Giewat, M | 1 |
| Seidman, CE | 1 |
| Seidman, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem[NCT00319982] | Phase 2/Phase 3 | 39 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adherence to study medication was assessed by pill count (NCT00319982)
Timeframe: Duration of the trial
| Intervention | percentage of pills taken (Median) |
|---|---|
| I- Diltiazem | 83 |
| II- Placebo | 90 |
The number of participants who developed overt left ventricular hypertrophy during the duration of the trial was analyzed (NCT00319982)
Timeframe: Baseline through final study visits
| Intervention | participants (Number) |
|---|---|
| I- Diltiazem | 2 |
| II- Placebo | 2 |
Change in Value (Difference between Final and Baseline Visits) (NCT00319982)
Timeframe: Baseline and final study visits
| Intervention | beats/minute (Mean) |
|---|---|
| I- Diltiazem | -4.9 |
| II- Placebo | 2.0 |
Change in Value (Difference between Final and Baseline Visits) (NCT00319982)
Timeframe: Baseline and final study visits
| Intervention | mmHg (Mean) |
|---|---|
| I- Diltiazem | -1.4 |
| II- Placebo | 2.1 |
The change in E' velocity (difference between final value - baseline value) was compared between participants who received diltiazem and those who received placebo to gauge treatment response. Please note that the total duration on treatment varied between study subjects to maximize time on treatment for the trial. Specifically, subjects that enrolled earliest had the longest duration of treatment; those who enrolled latest had the shortest duration of treatment with a minimum treatment duration of 1 year. All analyses examine the final study visit on treatment to the baseline visit. (NCT00319982)
Timeframe: Baseline and final study visits
| Intervention | cm/sec (difference final-baseline) (Mean) |
|---|---|
| I- Diltiazem | -0.06 |
| II- Placebo | -0.21 |
Change in Left Ventricular End-Diastolic Diameter z-score (Final Value - Baseline Value) (NCT00319982)
Timeframe: Baseline and final study visits
| Intervention | z-score units (Mean) |
|---|---|
| I- Diltiazem | 0.60 |
| II- Placebo | -0.53 |
Adverse events were compared between participants assigned to diltiazem and those assigned to placebo (NCT00319982)
Timeframe: Baseline through final study visits
| Intervention | Participants Reporting Adverse Events (Number) |
|---|---|
| I- Diltiazem | 10 |
| II- Placebo | 12 |
2 other studies available for minoxidil and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Unusual cases of resistance to minoxidil therapy.
Topics: Adult; Aged; Blood Pressure; Cardiomyopathy, Hypertrophic; Cardiovascular System; Catecholamines; Dr | 1980 |
An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy.
Topics: Animals; Calcineurin Inhibitors; Calcium; Cardiomyopathy, Hypertrophic; Cyclosporine; Echocardiograp | 2000 |